100th Patient Enrolled in ROADS Phase 3 Clinical Trial
Our enrollment of the 100th patient in the ROADS GammaTile® Clinical Trial marks a pivotal moment. This trial focuses on newly diagnosed metastatic brain tumors.
Our enrollment of the 100th patient in the ROADS GammaTile® Clinical Trial marks a pivotal moment. This trial focuses on newly diagnosed metastatic brain tumors.
GT Medical Technologies’ new CEO, Per Langoe, was interviewed by MedTech Dive about his plans to partner with healthcare providers and drive the adoption of GammaTile®, the only FDA-cleared revolutionary innovation in brain brachytherapy.
Vice President of Marketing, Jane Steen, shared thought-provoking insights in an interview discussing the dynamic evolution of point-of-care marketing. Explore the key highlights here.
Facing glioblastoma, Gilbert Stuart found hope with GammaTile introduced by Dartmouth Hitchcock Medical Center
During these uncertain times, remember to proactively reach out to patients and encourage them to resume routine cancer screenings to prevent delayed diagnoses that might lead to worsened health outcomes.
Matt Likens describes GammaTile Therapy, GT Medical Technologies’ mission, and how working with Silicon Valley Bank has helped GT Medical achieve their purpose of improving the lives of patients with brain tumors.
Orange Park Medical Center is the first hospital in North Florida to provide a new brain tumor treatment the size of a computer chip.
North Carolina CBS | Vidant Health™ and ECU Brody School of Medicine successfully perform first-in-state GammaTile procedure
Ohio CBS | New brain cancer therapy provides radiation right at tumor site
Cronkite News, Arizona PBS | Battling brain tumors with time-released radiation